Latest Partnerships News

First Graphene Limited’s partnership with Halocell Energy and QUT has yielded a breakthrough in perovskite solar cells, doubling efficiency to 30.6% while cutting production costs by up to 80%. This innovation paves the way for scalable, low-cost solar solutions across multiple industries.

Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.

Dubber Corporation Limited will record a significant non-cash impairment charge in FY25 following the loss of a major customer contract with Virgin Media O2, impacting its intangible assets from a prior acquisition.

DataDot Technology Limited reported a 13% revenue increase and a 56% rise in net profit after tax for FY25, driven by growth in its PropertyVAULT insurance services and new distributor partnerships.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Atturra Limited has become the first Australian Microsoft Solutions Partner to earn the Private Cloud Solution Partner designation, underscoring its leadership in sovereign and hybrid cloud services for critical sectors.

Australis Oil & Gas reported a reduced half-year loss and positive cash flow despite lower production, while actively seeking a development partner for its Tuscaloosa Marine Shale assets.

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.